 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...1617181920212223242526...208209» |
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Clinical, Retrospective data, Journal: Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase ? trial. (Pubmed Central) - Dec 10, 2025
P3
Furthermore, hetrombopag manifested favorable safety profile in patients with persistent ITP, and safety outcomes were comparable with those in chronic and overall ITP populations. Hetrombopag showed favorable safe and efficacy profile in patients with persistent ITP, aligning with results observed in patients with chronic ITP and overall ITP.
- || tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma
P1 data, Journal, First-in-human: TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study. (Pubmed Central) - Dec 9, 2025
P1
No significant correlation was found between TROP-2 expression and treatment efficacy. In summary, SHR-A1921 exhibited promising antitumor activity and a manageable safety profile, with 3.0 mg/kg every 3 weeks selected for further clinical development.
- || AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
P2 data, Journal: Comment on "Neoadjuvant immunochemotherapy with adebrelimab combined with the TP regimen for locally advanced OSCC: early results of a single-arm phase II clinical trial". (Pubmed Central) - Dec 9, 2025
In summary, SHR-A1921 exhibited promising antitumor activity and a manageable safety profile, with 3.0 mg/kg every 3 weeks selected for further clinical development. No abstract available
- | Journal: An LC-MS/MS method for simultaneous quantification of pyrotinib, docetaxel and paclitaxel in human plasma and its application to therapeutic drug monitoring. (Pubmed Central) - Dec 8, 2025
The therapeutic drug monitoring results showed that the plasma concentration of pyrotinib, docetaxel and paclitaxel varied significantly among individuals. Therapeutic drug monitoring for pyrotinib, docetaxel and paclitaxel is essential for individualized treatment to ensure efficacy and safety.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: RJBLC-NEBC001: Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma (clinicaltrials.gov) - Dec 8, 2025
P2, N=22, Recruiting, Sponsor: RenJi Hospital
Therapeutic drug monitoring for pyrotinib, docetaxel and paclitaxel is essential for individualized treatment to ensure efficacy and safety. Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
- || HRS-7535 / Kailera Therapeutics
New P1 trial: A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects (clinicaltrials.gov) - Dec 8, 2025
P1, N=40, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- ||| AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
P3 data, Retrospective data, Journal: Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a post hoc analysis from a phase III trial. (Pubmed Central) - Dec 8, 2025
P3
Ivarmacitinib significantly reduces the need for adding/escalating medications compared to placebo, thereby potentially decreasing treatment burden. However, the post hoc, exploratory nature of this study requires further validation for the findings.
- | Retrospective data, Review, Journal: Comparative efficacy and safety of second-line therapies for patients with advanced hepatocellular carcinoma: a systematic review and network meta-analysis of randomized controlled trials. (Pubmed Central) - Dec 8, 2025
A thorough search was conducted up until 20 February 2025, across the PubMed, Medline, Embase, Cochrane Central, and Web of Science databases to find randomized controlled trials (RCTs) evaluating second-line monotherapies (such as Ramucirumab, Regorafenib, Pembrolizumab, Cabozantinib, and Apatinib) in adults with advanced HCC...Pembrolizumab and Ramucirumab had the most favorable balance of efficacy and tolerability among second-line treatments for advanced HCC and are indicated as optimal therapy alternatives to enhance clinical outcomes. https://www.crd.york.ac.uk/prospero/, identifier CRD420251010308.
- ||| AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
P2/3 data, Retrospective data, Journal: Ivarmacitinib improves patient-reported outcomes across multiple domains in patients with active ankylosing spondylitis: a post hoc analysis of a phase II/III trial. (Pubmed Central) - Dec 8, 2025
P2/3
Ivarmacitinib significantly enhances multiple dimensions of PROs in active AS patients, supporting its utility in managing PROs in AS. Switching to ivarmacitinib also provides substantial benefits, this indicates that initiating ivarmacitinib treatment, even after an initial period of placebo leads to meaningful improvements in PROs.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Development and validation of a two-dimensional liquid chromatography method for therapeutic drug monitoring of pyrotinib in human plasma. (Pubmed Central) - Dec 8, 2025
The developed 2D-LC analytical method not only demonstrates good precision, accuracy, recovery, and stability, but also is simple, rapid, feasible, and practical for TDM. It can be used for the concentration monitoring of pyrotinib in clinic, providing more scientific evidence for clinical practice.
- | Journal: Combination of anti-CD20 and hetrombopag in relapsed/refractory immune thrombocytopenia: a case series. (Pubmed Central) - Dec 8, 2025
The other two patients remained in sustained CR throughout the follow-up period. Combining anti-CD20 monoclonal antibody with hetrombopag may offer therapeutic benefits in patients with relapsed/refractory ITP.
- || carboplatin / Generic mfg., paclitaxel / Generic mfg., AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
P2 data, Journal: Neoadjuvant immunochemotherapy with adebrelimab combined with the TP regimen for locally advanced OSCC: early results of a single-arm phase II clinical trial. (Pubmed Central) - Dec 8, 2025
PD-L1 inhibitors combined with chemotherapy have promising preliminary efficacy in patients with resectable locally advanced OSCC. However, additional follow-up is needed to obtain more comprehensive survival data and further validate these initial observations.
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
Trial completion date, Trial primary completion date: Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC (clinicaltrials.gov) - Dec 6, 2025
P2, N=64, Recruiting, Sponsor: Henan Cancer Hospital
However, additional follow-up is needed to obtain more comprehensive survival data and further validate these initial observations. Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026
- | ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Trial completion: A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices (clinicaltrials.gov) - Dec 5, 2025
P1, N=51, Completed, Sponsor: Kailera
Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026 Active, not recruiting --> Completed
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
New P2 trial, Mismatch repair, MSI-H, dMMR: CATALIS: Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma?A Randomized, Non-comparative Phase 2 Study (clinicaltrials.gov) - Dec 5, 2025
P2, N=30, Not yet recruiting, Sponsor: Shanghai Zhongshan Hospital
- | Enrollment open: An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (clinicaltrials.gov) - Dec 5, 2025
P2, N=20, Recruiting, Sponsor: Fudan University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Hetrombopag for enhancing platelet engraftment after haploidentical allogeneic hematopoietic stem cell transplantation in patients with severe thalassemia: An observational study () - Dec 5, 2025 - Abstract #ASH2025ASH_9811;
P
Not yet recruiting --> Recruiting Graft-versus-host disease prophylaxis included cyclophosphamide at a total dose of 100 mg/kg (divided into two doses on day +3 and +4), methotrexate at 10 mg/m
- Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Comparative study of hetrombopag vs. eltrombopag in promoting platelet engraftment post-autologous hematopoietic stem cell transplantation: A multicenter clinical trial () - Dec 5, 2025 - Abstract #ASH2025ASH_9733;
Graft-versus-host disease prophylaxis included cyclophosphamide at a total dose of 100 mg/kg (divided into two doses on day +3 and +4), methotrexate at 10 mg/m This study is the first to demonstrate that hetrombopag significantly accelerates neutrophil and platelet engraftment in auto-HSCT patients compared to eltrombopag.
- Nailike (olverembatinib) / Takeda, Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma, Tasigna (nilotinib) / Novartis, Inhibikase
Efficacy and safety of pegylated interferon alfa-2b combined with tyrosine kinase inhibitors in chronic Phase chronic myeloid leukemia patients with TKI resistance or intolerance () - Dec 5, 2025 - Abstract #ASH2025ASH_9262;
Median follow-up was 72 weeks (range 24-96).Prior TKIs included imatinib, nilotinib, dasatinib, flumatinib,and olverembatinib.By June 30,2025.Sixteen, fourteen, ten, and eight patients completed therapy at weeks 24,48,72,and 96,respectively.Nine patients discontinued treatment due to adverse events.Molecular responses:Week 24: MMR 37.5% (6/16),DMR 6.3%(1/16),Week 48:MMR57.1% (8/14); Week 72: MMR40.0% (4/10); DMR 30.0% (3/10); Week 96: MMR 50.0% (4/8),DMR 25.0% (2/8).Safety:The most common AEs were flu-like symptoms and hematologic toxicities (predominantly grade 1-2).Dose reductions or extended dosing intervals (up to q2 weeks) of PEG IFN?-2b were implemented to manage AEs. Conclusion PEG IFN?-2b combined with TKIs significantly reduces BCR::ABL1 transcript levels, enabling patients with TKI-resistant or intolerant chronic-phase chronic myeloid leukemia (CP-CML) to achieve major molecular response (MMR) and even deep molecular response (DMR), with a favorable safety profile.
- HHPG-19K (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Mecapegfilgrastim for prophylaxis of immunochemotherapy-induced neutropenia in patients with diffuse large B-cell lymphoma: A multicenter pilot trial () - Dec 5, 2025 - Abstract #ASH2025ASH_9173;
P2
Conclusion : This study is the first to demonstrate that the long-acting G-CSF, mecapegfilgrastim, exhibits a favorable safety profile and effectively reduced the incidence and severity of CIN in DLBCL patients receiving R-CHOP or R-CHOP-like regimens. These findings support its potential as a prophylactic option in this population, warranting further investigation in large-scale randomized trials.
- Venclexta (venetoclax) / Roche, AbbVie, Itari (linperlisib) / Shanghai YingLi Pharma
Synergistic Remission of refractory cutaneous T-cell lymphoma by linperlisib plus venetoclax via targeting the PI3K/AKT/CREB-BCL-2/MCL-1 signaling axis. () - Dec 5, 2025 - Abstract #ASH2025ASH_9137;
Linperlisib suppresses BCL-2/MCL-1 expression by inhibiting the PI3K/AKT/CREB axis, synergizing with venetoclax to overcome resistance. This combination represents a novel therapeutic strategy for achieving durable remission in relapsed pcALCL.
- Itari (linperlisib) / Shanghai YingLi Pharma
Efficacy and safety of linperlisib combined with azacitidine in patients with lymphoma () - Dec 5, 2025 - Abstract #ASH2025ASH_9123;
Observed adverse events included: anemia (n=12, 85.7%), pneumonia (n=10, 71.4%), thrombocytopenia (n=6, 42.9%), febrile neutropenia (n=6, 42.9%), liver function impairment (n=4, 28.6%), nausea/vomiting (n=2, 14.3%), diarrhea (n=1, 7.1%), and hypersensitivity (n=1, 7.1%). Conclusion : The combination of linperlisib and azacitidine demonstrated promising efficacy and a manageable safety profile in patients with lymphoma.
- Gazyva (obinutuzumab) / Roche, Biogen, Itari (linperlisib) / Shanghai YingLi Pharma
The oral PI3Kdelta inhibitor Linperlisib and Obinutuzumab as response-dependent, first-line regimen for marginal zone lymphoma: A prospective single-arm Phase Ib/II Study () - Dec 5, 2025 - Abstract #ASH2025ASH_9056;
P1/2
Conclusion Front-line treatment with Linperlisib and Obinutuzumab in MZL demonstrated encouraging early efficacy with a manageable safety profile. Further enrollment and follow-up are ongoing to confirm these preliminary findings and better define the role of this response-adapted strategy in the first-line setting for MZL.
- Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia () - Dec 5, 2025 - Abstract #ASH2025ASH_8823;
P=N/A
Notably, IKZF1 plus patients harboring T315I mutation constitute a subgroup with dismal survival, likely associated with the down-regulation of p53 pathways, and they would benefit from allo-HSCT. Conversely, IKZF1 plus cases without ABL1 mutations exhibit a markedly favorable prognosis.
- Nplate (romiplostim) / Amgen
Trial in progress: Romiplostim N01 combined with immunosuppressive therapy in patients diagnosed with non-severe aplastic anemia, a Phase II study () - Dec 5, 2025 - Abstract #ASH2025ASH_8669;
P2
Conversely, IKZF1 plus cases without ABL1 mutations exhibit a markedly favorable prognosis. However, clinical data on romiplostim in NSAA remain limited, and no studies to date have evaluated the efficacy and safety of Romiplostim N01 in this population.Study Design and Methods We initiated a prospective, open-label, multi-centre, single-arm phase II trial (ChiCTR2500096280), conducted across multiple regions in China, to evaluate the efficacy and safety of Romiplostim N01 combined with cyclosporine or tacrolimus in patients diagnosed with NSAA and severe thrombocytopenia (platelet counts <30
- | Retrospective data, Journal: Efficacy and safety of TACE plus lenvatinib with PD-1 inhibitor for unresectable huge hepatocellular carcinoma: a multicenter retrospective cohort study. (Pubmed Central) - Dec 5, 2025
Compared with TACE plus lenvatinib, triple therapy with TACE, lenvatinib, and PD-1 inhibitor resulted in better PFS and OS. These findings support the consideration of this triple combination as a promising first-line treatment option for unresectable huge HCC and warrant further validation in prospective studies.
- | AiTan (rivoceranib) / HLB Bio Group, Stivarga (regorafenib) / Bayer, sorafenib / Generic mfg.
Review, Journal, IO biomarker: Innovative gene targeted treatments for osteosarcoma: a mini review of current clinical evidence and future prospects. (Pubmed Central) - Dec 5, 2025
However, the rarity of osteosarcoma, trial design limitations, and treatment-related toxicities remain critical barriers. This review synthesizes current evidence and underscores the need for biomarker-driven, multimodal strategies to overcome resistance and improve long-term outcomes in osteosarcoma management.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New trial: Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib (clinicaltrials.gov) - Dec 5, 2025
P=N/A, N=60, Not yet recruiting, Sponsor: Hubei Cancer Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD), sorafenib / Generic mfg.
Retrospective data, Journal: Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study. (Pubmed Central) - Dec 4, 2025
This review synthesizes current evidence and underscores the need for biomarker-driven, multimodal strategies to overcome resistance and improve long-term outcomes in osteosarcoma management. Camrelizumab plus TACE and sorafenib or lenvatinib may be a promising treatment approach for the clinical management of unresectable HCC patients.
- | Review, Journal, Checkpoint inhibition, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, MSI-H, dMMR: Neoadjuvant Immune Checkpoint Inhibition in MSI-H/dMMR Colorectal Cancer: A Systematic Review of Prospective Trials Evaluating Efficacy, Pathologic Response, and Surgical Outcomes. (Pubmed Central) - Dec 4, 2025
Neoadjuvant immunotherapy may become an alternative to surgery as the primary treatment for MSI-H/dMMR colorectal cancer if long-term quality of life is superior and toxicity and cost are competitive with standard surgical approaches. However, longer follow-up, predictive biomarkers, and randomized comparisons with upfront surgery are required before its routine clinical use.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Dalpiciclib plus endocrine therapy as adjuvant treatment for HR+/HER2- early breast cancer: updated results from the phase 3, DAWNA-A trial (Exhibit Hall) - Dec 4, 2025 - Abstract #SABCS2025SABCS_2480;
P3
Conclusions Addition of Dalp to adjuvant ET contiuned to show clinically meaningful improvement in IDFS within and beyond the 2-yr treatment period, with a manageable safety profile. These findings support the adjuvant use of Dalp for HR+/HER2- EBC.
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Journal, PARP Biomarker: Radiosynthesis and PET evaluation of [18F]Fuzuloparib as a PARP-targeted imaging agent in breast cancer. (Pubmed Central) - Dec 3, 2025
These findings support the adjuvant use of Dalp for HR+/HER2- EBC. [18F]Fuzuloparib showed high tumor accumulation (peak 9.06
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Real-world evidence: Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response. (Pubmed Central) - Dec 3, 2025
Both HP and HPy combined with chemotherapy can be considered as optional NAT regimens for HER2-positive BC. The nomogram incorporating common clinical indicators provides a basis for clinicians to predict NAT efficacy at an earlier stage.
- | Itari (linperlisib) / Shanghai YingLi Pharma
Journal: Low-Dose Linperlisib Achieves Rapid Hematologic Response in a Patient with Pure Red Cell Aplasia and Severe Renal Insufficiency: A Case Report. (Pubmed Central) - Dec 3, 2025
The nomogram incorporating common clinical indicators provides a basis for clinicians to predict NAT efficacy at an earlier stage. No abstract available
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment change, Trial completion date, Trial primary completion date: Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 2, 2025
P2, N=18, Recruiting, Sponsor: Peking Union Medical College Hospital
No abstract available N=45 --> 18 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
- | cytarabine / Generic mfg., Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
Journal: Concurrent NPM1::CCDC28A and BCR::ABL1 fusions in extramedullary blast crisis of chronic myeloid leukemia: A case report and literature review. (Pubmed Central) - Dec 2, 2025
The patient achieved deep molecular remission of chronic-phase CML (BCR::ABL1 0.0058% International Scale) while receiving flumatinib, yet developed a painful sacrococcygeal mass...Intermediate-dose cytarabine with continued tyrosine-kinase inhibition produced marked metabolic regression on PET-CT, and the patient has been bridged to allogeneic hematopoietic stem-cell transplantation...Co-occurrence of BCR::ABL1 and NPM1::CCDC28A may delineate a distinct EMBC subset with prognostic and therapeutic relevance. Prospective studies are required to clarify the fusion's pathogenic role and biomarker potential.
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P2 trial: Herombopag Treated T-DM1 Induced Platelet Reduction (clinicaltrials.gov) - Dec 2, 2025
P2, N=56, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Aqupla (nedaplatin) / Simcere, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab combined with albumin-paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma: A multicenter, single-arm, phase II clinical study. (Level 1, West Hall; Poster Bd #: E17) - Dec 2, 2025 - Abstract #ASCOGI2026ASCO_GI_332;
P2
Prospective studies are required to clarify the fusion's pathogenic role and biomarker potential. Clinical Trial Registration Number: NCT06508229 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Neoadjuvant adebrelimab plus SOX and nab-paclitaxel in resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: A multicentre, single-arm, prospective phase II trial. (Level 1, West Hall; Poster Bd #: C1) - Dec 2, 2025 - Abstract #ASCOGI2026ASCO_GI_268;
P2
Clinical Trial Registration Number: NCT06508229 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2400082697 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (RICE): A prospective, phase 2 trial. (Level 1, West Hall; Poster Bd #: A23) - Dec 2, 2025 - Abstract #ASCOGI2026ASCO_GI_239;
P2
Clinical Trial Registration Number: ChiCTR2400082697 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST. Clinical Trial Registration Number: NCT06510660 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST.
- | Enrollment change, Checkpoint inhibition: ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC (clinicaltrials.gov) - Dec 1, 2025
P2, N=300, Recruiting, Sponsor: Peking Union Medical College Hospital
Clinical Trial Registration Number: NCT06510660 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST. N=100 --> 300
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
Enrollment open, Trial completion date, Trial primary completion date: Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer (clinicaltrials.gov) - Dec 1, 2025
P2, N=39, Recruiting, Sponsor: Women's Hospital School Of Medicine Zhejiang University
N=100 --> 300 Not yet recruiting --> Recruiting | Trial completion date: Dec 2029 --> Dec 2031 | Trial primary completion date: Sep 2029 --> Dec 2026
- |||| SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment open: SHR-A2102-212: A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 1, 2025
P2, N=300, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting | Trial completion date: Dec 2029 --> Dec 2031 | Trial primary completion date: Sep 2029 --> Dec 2026 Not yet recruiting --> Recruiting
- ||| GSK5784283 / GSK
Enrollment open: A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis (clinicaltrials.gov) - Dec 1, 2025
P2, N=70, Recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || carboplatin / Generic mfg., pemetrexed / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal: First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China. (Pubmed Central) - Dec 1, 2025
P2
Further investigation is warranted in a randomised controlled trial. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: A Long-Term Survival Case Report of a Patient with Pulmonary Sarcomatoid Carcinoma Accompanied by Brain Metastasis: Implications for Immunotherapy. (Pubmed Central) - Dec 1, 2025
After 4 cycles of chemotherapy combined with camrelizumab, the patient received monotherapy with immunotherapy...For patients with PSC, genetic testing is necessary. The efficacy of immunotherapy in patients with PSC is worthy of expectation.
- | oxaliplatin / Generic mfg., retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma, capecitabine / Generic mfg.
Journal: Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer. (Pubmed Central) - Nov 28, 2025
P2
One patient experienced fatal immune-mediated myocarditis prior to surgery. Overall, the addition of SHR-1701 to CRT demonstrated encouraging efficacy and manageable safety in high-risk LARC, supporting further investigation in larger randomized trials.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Non-intravenous chemotherapy-sparing triplet of dalpiciclib/pyrotinib/endocrine therapy () - Nov 28, 2025 - Abstract #ABC82025ABC8_135;
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Clinical, P2 data, Journal: Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study. (Pubmed Central) - Nov 27, 2025
Pyrotinib plus trastuzumab demonstrates clinically meaningful efficacy and a manageable safety profile in heavily pretreated HER2-positive metastatic colorectal cancer. These findings support advancing this regimen as a potential alternative in refractory HER2-positive mCRC, particularly in the RAS/BRAF wild-type subgroup.
- AiRuiKa (camrelizumab) / HLB Bio Group
Clinical protocol, Journal, Real-world evidence: Effect of angiotensin II receptor blockers on efficacy and safety of Camrelizumab plus chemotherapy in the first-line therapy for advanced non-small cell lung cancer (ARMOR I): a protocol for a prospective, real-world, multicenter, intervention clinical trial. (Pubmed Central) - Nov 27, 2025
ARMOR I will provide crucial preliminary data on ARB's role in first-line therapy for advanced NSCLC. The potential application of ARB in other tumor types may also become an important area to explore.